Case D C, Young C W, Lee B J
Cancer. 1977 Apr;39(4):1382-6. doi: 10.1002/1097-0142(197704)39:4<1382::aid-cncr2820390405>3.0.co;2-f.
Twenty-four patients with advanced Hodgkin's disease, resistant to the MOPP regimen, were treated with a combination of Adriamycin, bleomycin, dacarbazine and vinblastine (ABDV). Fifteen (63%) achieved objective remission, 14 partial remissions and one complete remission. The median duration of remission in this group of patients was 6.5 months; four of the 15 patients are still in remission (8+, 8+, 9+, 10+ months). Objective remission occurred rapidly within 1.5 months. Regression was evident in disease within nodes, lung, liver and bone. Toxic manifestations caused by ABDV were well tolerated and reversible. In one patient death was directly attributed to drug toxicity. This combination has produced a better rate and duration of remission than that reported with single agent chemotherapy in MOPP-resistant patients with Hodgkin's disease. In our hands, ABDV did not equal the recent results reported with Bleomycin-CCNU-Velban in a seemingly similar group of patients.
24例对MOPP方案耐药的晚期霍奇金病患者接受了阿霉素、博来霉素、达卡巴嗪和长春花碱联合化疗（ABDV）。15例（63%）获得客观缓解，14例部分缓解，1例完全缓解。该组患者缓解期的中位数为6.5个月；15例患者中有4例仍处于缓解状态（8+、8+、9+、10+个月）。客观缓解在1.5个月内迅速出现。淋巴结、肺、肝和骨内的病灶明显消退。ABDV引起的毒性表现耐受性良好且可逆转。1例患者死亡直接归因于药物毒性。与MOPP耐药的霍奇金病患者单药化疗相比，该联合化疗方案产生了更好的缓解率和缓解持续时间。在我们的研究中，ABDV的疗效不及最近报道的博来霉素-环己亚硝脲-长春碱在一组看似相似患者中的治疗结果。
